Telix Pharmaceuticals (TLPPF) Total Non-Current Liabilities (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Total Non-Current Liabilities for 4 consecutive years, with $631.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $631.8 million in Q2 2026; TTM through Jun 2026 was $631.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $517.0 million, changed 0.01% from the prior year.
• Total Non-Current Liabilities was $631.8 million for Q2 2026 at Telix Pharmaceuticals, up from $517.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $631.8 million in Q2 2026 and troughed at $59.9 million in Q4 2023.
• A 4-year average of $403.1 million and a median of $460.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities soared 574.17% in 2024 and grew 28.06% in 2025, its largest moves.
• Over 4 years, Total Non-Current Liabilities stood at $59.9 million in 2023, then soared by 574.17% to $403.7 million in 2024, then gained by 28.06% to $517.0 million in 2025, then climbed by 22.21% to $631.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $631.8 million (Q2 2026), $517.0 million (Q4 2025), and $403.7 million (Q4 2024), per Business Quant data.